MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Country |
 USA |
IPO year |
2004 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITALSPB |
Shares |
104 M |
Market Cap[1] |
$ 4.84 B |
EBITDA (LTM) |
$ 80.9 M |
P/E (LTM) |
40.16 |
P/S (LTM) |
6.52 |
EPS (LTM) |
1.16 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Aptorum Group Limited
APM
|
$ 0.89 | - | $ 6.54 M | Nasdaq Global Select Market | China |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | France |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 22.2 | - | $ 3.68 B | Nasdaq Global Select Market,SPB | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Edesa Biotech
EDSA
|
$ 15.9 | - | $ 50.8 M | Nasdaq Capital Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Evogene Ltd.
EVGN
|
$ 0.76 | - | $ 27.9 M | Nasdaq Global Market |  Israel |
 |
Exelixis
EXEL
|
$ 44.69 | - | $ 12.1 B | Nasdaq Global Select Market,SPB | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Galapagos NV
GLPG
|
$ 27.86 | - | $ 2.69 B | Nasdaq Global Select Market |  Belgium |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Grifols, S.A.
GRFS
|
$ 7.91 | - | $ 6.83 B | Nasdaq Global Select Market |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
$ 31.05 | - | $ 1.79 B | Nasdaq Global Select Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
ImmuCell Corporation
ICCC
|
$ 8.44 | - | $ 76.2 M | Nasdaq Global Select Market | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market | USA |
 |
BioNTech SE
BNTX
|
$ 101.57 | - | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Immuron Limited
IMRN
|
$ 0.81 | 0.3 % | $ 9.47 M | Nasdaq Global Select Market |  Australia |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Incyte Corporation
INCY
|
$ 99.1 | - | $ 19.3 B | Nasdaq Global Select Market,SPB | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
InMed Pharmaceuticals
INM
|
$ 0.7 | - | $ 1.71 M | Nasdaq Capital Market | Canada |
 |
INmune Bio
INMB
|
$ 1.33 | - | $ 32.9 M | Nasdaq Capital Market | USA |
 |
Innoviva
INVA
|
$ 23.05 | - | $ 1.55 B | Nasdaq Global Select Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Innate Pharma S.A.
IPHA
|
$ 1.48 | -0.67 % | $ 235 M | Nasdaq Global Select Market | France |
 |
Jaguar Health
JAGX
|
$ 7.88 | - | $ 18.4 M | Nasdaq Capital Market | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
KalVista Pharmaceuticals
KALV
|
$ 26.67 | - | $ 1.44 B | Nasdaq Global Select Market | Britain |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Kamada Ltd.
KMDA
|
$ 8.11 | - | $ 260 M | Nasdaq Global Select Market | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 2.98 | - | $ 4.91 M | NYSE American | Israel |
 |
Krystal Biotech
KRYS
|
$ 259.95 | - | $ 7.52 B | Nasdaq Global Market,SPB | USA |
 |
Kazia Therapeutics Limited
KZIA
|
$ 12.42 | - | $ 1.65 B | Nasdaq Global Select Market | Australia |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
$ 224.86 | - | $ 4.11 B | Nasdaq Global Select Market,SPB | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Liquidia Corporation
LQDA
|
$ 38.15 | - | $ 3.28 B | Nasdaq Capital Market | USA |
 |
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Aquestive Therapeutics
AQST
|
$ 4.05 | - | $ 433 M | Nasdaq Global Market | USA |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.